Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xyotax in Metastatic Breast Cancer
NCT00148707Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2004
- Primary completion
- Sep 2007
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel poliglumex in breast cancer, sponsored by Dana-Farber Cancer Institute. Primary endpoint: Objective Response Rate. Started Oct 2004; status: completed.
02
Drugs
paclitaxel poliglumex
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00148707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148707.